Oncology Central

Tumor heterogeneity-based resistance guides personalized cancer medicine


Recent evidence on tumor heterogeneity shapes a new era in achieving personalized cancer medicine. Indeed, despite advances in modern oncology with standardized single biopsy-based approaches, limitations still exist in predicting resistance to therapies and tumor progression.

To view restricted content, please:

Leave A Comment